ERBB2 and neoplasm: Although the exact mechanisms underlying primary and acquired resistance to HER2 targeted therapy are still under study, intra-tumor heterogeneity and the activations of downstream signaling pathways including several RTKs seem to be involved in tumor escape from HER2-blockade.